Locoregional infusion of EGFR806-CAR T cells for recurrent or refractory pediatric CNS tumors: Results of the completed BrainChild02 phase 1 clinical trial
Juliane Gust(University of Washington), Julie R. Park(Seattle Children's Hospital), Sowmya Pattabhi, Jason S. Hauptman(Seattle Children's Hospital), Ashley Wilson(Center for Infectious Disease Research), Nicholas A. Vitanza(Seattle Children's Hospital), Erin Crotty(Seattle Children's Hospital), Catherine M. Albert(Seattle Children's Hospital), Rebecca Ronsley(Seattle Children's Hospital), Francisco A. Perez(Seattle Children's Hospital), Sarah Leary(Seattle Children's Hospital), Stephanie Rawlings-Rhea(Seattle Children's Hospital), Bonnie Cole(Howard Hughes Medical Institute), Jason N. Wright(Seattle Children's Hospital), Jeffrey G. Ojemann(Seattle Children's Hospital), Jason Wendler(Pacific Northwest National Laboratory), Rebecca Gardner(Seattle Children's Hospital), Navin Pinto(Seattle Children's Hospital), Kristy Seidel(Fred Hutch Cancer Center), Samuel R. Browd(Seattle Children's Hospital), Amy S. Lee(University of Southern California), Christopher Brown, Nadezhda Shtanukhina(Seattle Children's Hospital), Michael C. Jensen(Seattle Children's Hospital)
Cited by 16
Related Papers
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
|New England Journal of Medicine|2016|1.8k
Intertumoral Heterogeneity within Medulloblastoma Subgroups
|Cancer Cell|2017|1.3k